Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
2.99 (USD) • At close April 17, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0.12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.374 | 0.373 | 0.195 | 0.183 | 0.182 | 0.011 | 0.022 | 0.035 | 0.109 | 0 | 0 | 0 |
| Gross Profit
| 0 | -0.374 | -0.373 | -0.195 | -0.063 | -0.182 | -0.011 | -0.022 | -0.035 | -0.109 | -0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | -0.525 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 51.964 | 30.312 | 27.08 | 23.735 | 6.131 | 8.128 | 6.817 | 2.022 | 25.024 | 32.638 | 14.577 | 12.201 | 7.37 |
| General & Administrative Expenses
| 18.613 | 12.688 | 12.7 | 13.132 | 10.052 | 6.056 | 7.243 | 11.099 | 13.099 | 12.623 | 8.885 | 3.548 | 2.279 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 18.613 | 12.688 | 12.7 | 13.132 | 10.052 | 6.056 | 7.243 | 11.099 | 13.099 | 12.623 | 8.885 | 3.548 | 2.279 |
| Other Expenses
| 0 | 0 | 0.462 | 0.007 | 0.079 | 0.04 | -0.005 | 0.005 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 70.577 | 43 | 39.78 | 36.867 | 16.183 | 14.184 | 14.06 | 13.121 | 38.123 | 45.261 | 23.462 | 15.749 | 9.649 |
| Operating Income
| 0 | -43 | 8.495 | -36.867 | -18.465 | -16.051 | -14.06 | -13.121 | -38.123 | -45.261 | -23.462 | -15.749 | -9.649 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | -153.875 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0 | 2.674 | 0.462 | 0.007 | -4.75 | 0.04 | -0.005 | 0.005 | -0.527 | 0.174 | 0.166 | 0.024 | 0 |
| Income Before Tax
| -35.753 | -40.326 | -87.966 | -36.86 | -23.215 | -16.011 | -14.065 | -13.116 | -37.959 | -45.087 | -23.296 | -15.725 | -9.649 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | -193.458 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0.431 | 0 | -0.462 | -2.354 | -0.404 | 1.867 | -0.005 | 0 | 0.136 | 0 | -0.187 | 0 | 0 |
| Net Income
| -35.322 | -40.326 | -87.504 | -34.506 | -22.811 | -17.878 | -14.065 | -13.116 | -37.959 | -45.087 | -23.296 | -15.725 | -9.649 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | -190.092 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.73 | -0.002 | -6.13 | -2.33 | -15.72 | -27.27 | -28.11 | -50.47 | -1,785.21 | -324.85 | -583.36 | -165.87 | -101.78 |
| EPS Diluted
| -0.073 | -1.64 | -6.13 | -2.33 | -15.72 | -27.27 | -28.11 | -50.47 | -1,785.21 | -324.85 | -583.36 | -165.87 | -101.78 |
| EBITDA
| 0 | 0 | -87.593 | -36.665 | -23.032 | -15.829 | -14.049 | -13.099 | -6.899 | -44.978 | -23.275 | -15.715 | -9.64 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | -191.933 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |